MedTrace Logo

Phase I/IIa Dose-escalation Clinical Study of VAC-3S

NCT01549119 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2015-02-02

No results posted yet for this study

Summary

The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.

Conditions

  • HIV-1 Infection

Interventions

BIOLOGICAL

VAC-3S

Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart

BIOLOGICAL

Placebo

Comparison with experimental vaccine

Sponsors & Collaborators

  • InnaVirVax

    lead INDUSTRY

Principal Investigators

  • Raphael Ho Tsong Fang, DVM, PHD · InnaVirVax

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-02-28
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01549119 on ClinicalTrials.gov